Wies Dooremalen's Contact Details

Wies Dooremalen's Company Details

Hubrecht Organoid Technology

Utrecht, Utrecht, Netherlands • 55 Employees
Biotechnology

Hubrecht Organoid Technology (HUB) was jointly founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW). It constitutes a paradigm-shifting platform for drug discovery and development, (pre)clinical patient stratification, predictive diagnostics, personalized medicine, and companion diagnostics. HUB exploits the pioneering work of Prof. Dr. Hans Clevers, who discovered methods how to grow ‘mini-organs' – organoids – out of stem cell-derived human epithelial tissue.HUB builds a comprehensive Living Biobank of well-characterized organoids and develops assays for drug screening and validation: The Organoid Technology. HUB offers licenses to its patented Organoid Technology for in-house drug-screening and access to organoids in the Living Biobank for in-house preclinical drug discovery and validation. In addition, HUB provides drug screening services to third parties. The platform provides an advanced translational medicine approach to validate candidate product leads, and guide the design of clinical trials based on patient stratification.